<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3125">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03066219</url>
  </required_header>
  <id_info>
    <org_study_id>BRM421-16-C001-PR</org_study_id>
    <nct_id>NCT03066219</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of BRM421 for Dry Eye Syndrome</brief_title>
  <official_title>A Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of BRM421 Ophthalmic Solution in Subjects With Dry Eye Using a Controlled Adverse Environment (CAE®) Model</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BRIM Biotechnology Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BRIM Biotechnology Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the safety and efficacy of BRM421 Ophthalmic
      Solution to placebo for the treatment of the signs and symptoms of dry eye.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2017</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sign: Corneal fluorescein staining score</measure>
    <time_frame>Up to 4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Symptom: Ocular discomfort score</measure>
    <time_frame>Up to 4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tear film break-up time</measure>
    <time_frame>Up to 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conjunctival Redness</measure>
    <time_frame>Up to 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular Surface Disease Index (OSDI)©</measure>
    <time_frame>Up to 4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Dry Eye Syndrome</condition>
  <arm_group>
    <arm_group_label>BRM421 Ophthalmic Solution</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BRM421</intervention_name>
    <description>A topical solution containing BRM421 active</description>
    <arm_group_label>BRM421 Ophthalmic Solution</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be at least 18 years of age;

          -  Provide written informed consent;

          -  Have a reported history of dry eye for at least 6 months prior to enrollment;

          -  Have a history of use of eye drops

        Exclusion Criteria:

          -  Have any clinically significant slit lamp findings at Visit 1 that may include active
             blepharitis, meibomian gland dysfunction (MGD), lid margin inflammation or active
             ocular allergies that require therapeutic treatment, and/or in the opinion of the
             investigator may interfere with study parameters;

          -  Be diagnosed with an ongoing ocular infection (bacterial, viral, or fungal), or
             active ocular inflammation at Visit 1;

          -  Have worn contact lenses within 7 days of Visit 1 or anticipate using contact lenses
             during the study;

          -  Have used any eye drops within 2 hours of Visit 1;

          -  Have previously had laser-assisted in situ keratomileusis (LASIK) surgery within the
             last 12 months;

          -  Be a woman of childbearing potential who is not using an acceptable means of birth
             control; acceptable methods of contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 23, 2017</lastchanged_date>
  <firstreceived_date>February 23, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
